3rd Annual

Macrocyclics and Constrained Peptides

Bigger, Better, But hopefully still Oral, Small Molecules

April 22-23, 2015 

 

Recent advances combining biological and chemical approaches to create libraries of small, synthetic macrocyclic molecules have created a new class of therapeutically promising compounds that exhibit desireable ‘middle ground’ characteristics – small enough to pass through the cell membrane and reach intracellular targets, with the potential to be delivered orally; but large enough to have better specificity for disrupting protein-protein interactions. This conference explores this emerging class of molecules and discusses the challenges they face as drug candidates. Join fellow drug discovery scientists for this day-and-a-half meeting that is in the second half of our larger Drug Discovery Chemistry event. 


 

This meeting was an eye-opener for me to see how collectively drug delivery scientists can work
with medicinal chemists to bring new pharmaceutical products more effectively to the market.

Hayat O., Professor, University of Illinois at Chicago


Day 1 | Day 2 | Download Brochure | Register 

Wednesday, April 22

12:30 pm Registration


EXPANDING THE RULE OF FIVE 

1:30 Chairperson’s Remarks

Nicholas Terrett, Ph.D., CSO, Ensemble

1:40 FEATURED SPEAKER: Understanding Permeability of Peptide and Peptidomimetic Macrocycles

Spiro Liras, Ph.D., Vice President, Worldwide Medicinal Chemistry, CVMED, Pfizer

2:10 Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates

Jan Kihlberg, Ph.D., Professor, Department of Chemistry, BMC, Uppsala University, Sweden

Analysis of a comprehensive set of drugs and clinical candidates having MW >500 Da demonstrate significant opportunities for discovery of cell permeable and orally bioavailable drugs in physicochemical space far beyond the rule of 5 (bRo5). As compared to Ro5 compliant drugs, those bRo5 may modulate different kinds of targets, in particular ones having flat and groove shaped binding sites. Interestingly, macrocycles appear to have features that provide special opportunities in bRo5 drug space.

2:40 Towards Design Rules for Macrocycles

Adrian Whitty, Ph.D., Department of Chemistry, Biomolecular Engineering Research Center, Boston University

The potential utility of synthetic macrocycles as drugs, particularly against challenging targets such as protein-protein interactions, has been widely discussed. We have analyzed the binding modes of a representative set of macrocycle-protein complexes. The results allow us to propose specific guidelines for the design of synthetic macrocycles libraries possessing structural and physicochemical features likely to favor strong binding to protein targets and also good bioavailability.

3:10 Approaching Macrocyclic Chemical Space through Non-Conventional Routes

Scott Breinin, Ph.D., Senior Medicinal Chemist, Medicinal Chemistry, Asinex Corporation

At Asinex, over a 5 year period of macrocyclic synthetic development, we have learned many lessons, developed new approaches, and also created a platform that uses macrocycles as the core element in the design of novel peptidomimetic molecules. These structures have the correct geometry and substitution characteristics to align the requisite functional groups in three dimensions and are thus able to disrupt key elements of the PPI interface. This talk will focus on how this strategy addresses an unmet need in drug discovery. We will also touch on lessons learned in our history of macrocyclic development.

3:40 Celebratory 10th Annual Refreshment Break in the Exhibit Hall with Poster Viewing

4:20 Constrained Cyclic Peptides: Conformation vs. Bioavailability

David P. Fairlie, Ph.D., Professor and Head, Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, University of Queensland

We live in a new age of injectable peptide drugs. Exponential growth in protein/peptide therapeutics will continue due to the increasing need to target larger, shallower, interacting protein surfaces. To achieve potency and high selectivity, larger molecules with additional chemical foliage are required. Cyclic peptides provide opportunities to increase molecular size and interactions, while constraining ligands into pre-organized protein-binding conformations. What limits the conversion of cyclic peptides into potent, selective and orally bioavailable drugs?

4:50 Structural Basis of Macrocycle-Enzyme Interaction

Markus Seeliger, Ph.D., Assistant Professor, Pharmacological Sciences, Stony Brook University

We have determined the co-crystal structures of unusually specific macrocyclic inhibitors of protein kinases and proteases. These macrocycles were derived from a DNA-templated library of macrocycles. Currently, there are few synthetic macrocycles in clinical use. In fact, there is only a small number of protein co-crystal structures with macrocyclic compounds. Our recently published co-crystal structures of Src and IDE in complex with macrocyclic inhibitors gives new insights into the way these compounds achieve specificity.

5:20 Breakout Discussions

In this session, attendees choose a specific roundtable discussion to join. Each group has a moderator to ensure focused conversations around key issues within the topic. The small group format allows participants to informally meet potential collaborators, share examples from their work and discuss ideas with peers. Check our website in February to see the full listing of breakout topics and moderators.

6:20 Close of Day

6:30 Dinner Short Courses*

*Separate registration required; please see page 4 for details


Day 1 | Day 2 | Download Brochure | Register 

Thursday, April 23

8:00 am Morning Coffee

»8:30 PLENARY KEYNOTE PRESENTATION: 

Fragment-Based Drug Discovery: A Fifteen Year (Re-)Evolution

Harren JhotiHarren Jhoti, Ph.D., President & CEO, Astex Pharmaceuticals

Fragment-based discovery has now been successfully established as an alternative approach to HTS and has produced multiple drug candidates that are in clinical trials. Some of the appealing features of the approach include the ability to efficiently sample chemical space and to produce drug candidates that have superior physicochemical properties. In this talk I will provide a perspective on how Fragment-Based drug discovery evolved over the last 15 years and challenged conventional thinking in Drug Discovery.


9:30 Coffee Break in the Exhibit Hall with Poster Viewing


CASE STUDIES: PROGRESSING IN THE DEVELOPMENT PIPELINE 

10:10 Chairperson’s Remarks

Tomi Sawyer, Ph.D., Director, Peptide Therapeutics, Merck

10:15 Exploring Macrocycles for Protein-Protein Interaction Targets: the Discovery of Novel Bifunctional XIAP Antagonists

Nicholas Terrett, Ph.D., CSO, Ensemble

Macrocycles are found widely in nature and several are marketed as drugs with good pharmaceutical properties. This talk will describe how Ensemble can rapidly generate millions of synthetic macrocycles using DNA-programmed chemistry, and how they are efficiently screened against protein-protein interaction targets to identify hit compounds and SAR. The novel approach will be illustrated with successful examples of lead discovery programs, including the discovery of novel dimeric macrocyclic XIAP antagonists.

10:45 A Novel Cyclic Peptide Drp1 Inhibitor Diminishes Aberrant Mitochondrial Fission

Nir Qvit, Ph.D., Postdoctoral Fellow, Chemical and Systems Biology, Stanford University

I will address several key issues regarding constrained peptides, such as, cyclization, peptidomimetic and peptide modification. Excessive mitochondrial fission is associated with the pathology of a number of neurodegenerative diseases. Therefore, inhibitors of aberrant mitochondrial fission could provide important research tools in addition to potential leads for drug development. Using a rational approach, we designed a novel and selective cyclic peptide inhibitor of excessive mitochondrial fission. This novel cyclic peptide inhibits Drp1 enzyme activity and blocks Drp1/Fis1 interaction in vitro and in cultured neurons. I will present some unpublished data from our lab to support my conclusions.

11:15 Sponsored Presentation (Opportunity Available)

11:30 A Macrocyclic Peptide Inhibitor of Complement C5 as an Alternative to Monoclonal Antibody Therapy

Douglas A. Treco, Ph.D., President and CEO, Ra Pharmaceuticals, Inc.

12:00 pm Optimization of a Stapled Peptide

Tomi Sawyer, Ph.D., Director, Peptide Therapeutics, Merck

12:30 Walk and Talk Luncheon in the Exhibit Hall with Poster Viewing (last chance for viewing)


NEW TARGETS FOR MACROCYCLICS 

1:40 Chairperson’s Remarks

Eric Marsault, Ph.D., Professor, Pharmacology, University of Sherbrooke

1:45 p53/HDM2 Case Study: Macrocyclic Organo-Peptide Hybrids as Molecular Scaffolds for Targeting PPIs

Rudi Fasan, Ph.D., Associate Professor, Department of Chemistry, University of Rochester

This talk will present novel methodologies developed in our group for constructing macrocycles with a hybrid peptidic/non-peptidic backbone through the embedding of non-proteogenic, synthetic elements into genetically encoded peptidic frameworks. In recent studies, we established that these macrocyclic scaffolds can readily accommodate a-helical protein binding motifs. A case study will be discussed in which this strategy was applied to obtain macrocyclic inhibitors of the p53:HDM2 interaction that display dual specificity against the HDMX homolog as well as favorable proteolytic stability and cell penetration properties.

2:15 Nonimmunosuppressive Cyclophilin Inhibitors as Antiviral and Cytoprotective Agents: the Discovery of Cyclosporines with Improved Pharmaceutical Properties

Jiping Fu, Ph.D., Senior Investigator III, Medicinal Chemistry, Novartis

Chemical modification of the cyclosporine scaffold has led to the discovery of non-immunosuppressive analogs that have potential utility for treating diverse viral infections, inflammatory diseases and mitochondrial disorders. We have prepared new non-immunosuppressive cyclosporine analogs with excellent pharmaceutical and pharmacokinetic properties. This talk will describe the chemical biology of non-immunosuppressive cyclophilin inhibitors, details of our lead optimization effort, and the preclinical profile of the clinical candidate NIM258 for treating HCV infection.

2:45 Refreshment Break


MACROCYCLIC KINASE INHIBITORS 

3:00 Nanocyclix Approach towards Unexplored Kinases: Identification of RIP2 and SIK2 Inhibitors for Application in Auto-Immune and CNS Disorders

Jan Hoflack, Ph.D., CSO, Oncodesign Biotechnology

Oncodesign’s chemical biology approach using its macrocyclic chemistry platform has allowed the identification of potent and selective inhibitors for RIP2 and SIK2 kinases. The molecules have been used as chemical probes to validate the potential of these novel targets. Data will be presented that demonstrate the potential role of RIP2 as a target of interest in auto-immune diseases and for SIK2 in neuroprotection/ageing. The discovery and optimization of the inhibitors will be presented.

3:30 PF-06463922, a Novel Small Molecule Inhibitor of ALK/ROS1 with Preclinical Brain Availability and Broad Spectrum Potency against ALK-Resistant Mutations

Ted W. Johnson, Ph.D., Research Fellow, Medicinal Chemistry, Pfizer Oncology

PF-06463922, a novel macrocyclic inhibitor of ALK/ROS1, demonstrated low nanomolar inhibitory activity against a panel of ALK kinase domain mutants representing all of the patient crizotinib resistant mutations reported to date. Successful optimization of molecular weight and lipophilic efficiency leveraging structure-based drug design techniques led to ligands with overlapping broad spectrum potency, low transporter efflux, and brain penetration. PF-06463922 is currently in Phase 1/2 clinical trials.

4:00 Discovery of SB1578 - A JAK2 Small Molecule Macrocycle for Autoimmune Diseases

Anthony D. William, Ph.D., Senior Scientist, The Agency for Science, Technology and Research (A*STAR)-ICES

SB1578 is a novel, orally bioavailable JAK2 inhibitor with specificity for JAK2 within the JAK family and also demonstrates potent activity against FLT3 and c-Fms. These three tyrosine kinases play a pivotal role in activation of pathways that underlie the pathogenesis of rheumatoid arthritis. Herein the design and optimization of the macrocyclic Jak2/Flt3 inhibitor will be discussed including the biochemical and cellular activities of SB1578 that translate into its high efficacy in rodent models of arthritis.

4:30 Close of Conference


Day 1 | Day 2 | Download Brochure | Register